{"title":"Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives.","authors":"Francesco Costa,Juan Jose Gomez Doblas,Arancha Díaz Expósito,Marianna Adamo,Fabrizio D'Ascenzo,Lukasz Kołtowski,Luca Saba,Guiomar Mendieta,Felice Gragnano,Paolo Calabrò,Lina Badimon,Borja Ibañez,Roxana Mehran,Dominick J Angiolillo,Thomas Lüscher,Davide Capodanno","doi":"10.1093/eurheartj/ehaf474","DOIUrl":null,"url":null,"abstract":"Recent advances in artificial intelligence (AI) have shown great potential in improving cardiovascular pharmacotherapy by optimizing drug selection, predicting therapeutic efficacy and adverse effects, ultimately improving patient outcomes. Leveraging techniques like machine learning and in silico modelling, AI can identify populations likely to benefit from specific treatments, expedite novel drug discovery and reduce costs. Computational methods can also facilitate the detection of drug interactions and tailor interventions based on real-world data, supporting personalized care. Artificial intelligence-based approaches also show promise in streamlining clinical trial design and execution, leveraging on real-time data on patient responsiveness, enhancing recruitment efficiency. However, in order to fully realize these benefits, robust validation across diverse patient populations is necessary to ensure accuracy and generalizability. In addition, addressing concerns regarding data quality, privacy, and bias is equally critical to avoid exacerbating existing healthcare disparities. Scientific societies and regulatory agencies must ultimately establish standardized frameworks for data management, model certification, and transparency, to enable safe and effective integration of AI into clinical practice. This manuscript aims at systematically reviewing the current state-of-the-art applications of AI in cardiovascular pharmacotherapy, describing their current potential in guiding treatment decisions, refine trial methodologies and support drug discovery.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"94 1","pages":""},"PeriodicalIF":37.6000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurheartj/ehaf474","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Recent advances in artificial intelligence (AI) have shown great potential in improving cardiovascular pharmacotherapy by optimizing drug selection, predicting therapeutic efficacy and adverse effects, ultimately improving patient outcomes. Leveraging techniques like machine learning and in silico modelling, AI can identify populations likely to benefit from specific treatments, expedite novel drug discovery and reduce costs. Computational methods can also facilitate the detection of drug interactions and tailor interventions based on real-world data, supporting personalized care. Artificial intelligence-based approaches also show promise in streamlining clinical trial design and execution, leveraging on real-time data on patient responsiveness, enhancing recruitment efficiency. However, in order to fully realize these benefits, robust validation across diverse patient populations is necessary to ensure accuracy and generalizability. In addition, addressing concerns regarding data quality, privacy, and bias is equally critical to avoid exacerbating existing healthcare disparities. Scientific societies and regulatory agencies must ultimately establish standardized frameworks for data management, model certification, and transparency, to enable safe and effective integration of AI into clinical practice. This manuscript aims at systematically reviewing the current state-of-the-art applications of AI in cardiovascular pharmacotherapy, describing their current potential in guiding treatment decisions, refine trial methodologies and support drug discovery.
期刊介绍:
The European Heart Journal is a renowned international journal that focuses on cardiovascular medicine. It is published weekly and is the official journal of the European Society of Cardiology. This peer-reviewed journal is committed to publishing high-quality clinical and scientific material pertaining to all aspects of cardiovascular medicine. It covers a diverse range of topics including research findings, technical evaluations, and reviews. Moreover, the journal serves as a platform for the exchange of information and discussions on various aspects of cardiovascular medicine, including educational matters.
In addition to original papers on cardiovascular medicine and surgery, the European Heart Journal also presents reviews, clinical perspectives, ESC Guidelines, and editorial articles that highlight recent advancements in cardiology. Additionally, the journal actively encourages readers to share their thoughts and opinions through correspondence.